Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655754 | 0.85 | MLYCD (0.49) | MLYCDMAPTL3MBTL1CES1 | |
| SCHEMBL15000339 | 0.85 | TP53 (0.58) | MLYCDL3MBTL1GAA | |
| SCHEMBL18419287 | 0.85 | PKM (0.66) | MLYCDMAPTRAB9AL3MBTL1NPC1 | |
| SCHEMBL22386745 | 0.85 | MAPT (0.56) | MAPTRAB9AL3MBTL1NPC1PKM | |
| SCHEMBL15828758 | 0.83 | MAPT (0.54) | MAPTRAB9AL3MBTL1NPC1PKM | |
| SCHEMBL8444552 | 0.81 | PARP10 (0.59) | MLYCDMAPTRAB9ANPC1PLK1 | |
| SCHEMBL7632127 | 0.81 | KDM4E (0.52) | MLYCDMAPTRAB9ANPC1 | |
| SCHEMBL7246449 | 0.81 | TP53 (0.67) | MLYCDGAA | |
| SCHEMBL15000394 | 0.81 | TP53 (0.67) | MLYCDGAA | |
| SCHEMBL7247487 | 0.81 | TP53 (0.67) | MLYCDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | MLYCD 4298/4885MAPT 480/4885RAB9A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.